Extension at 10 Years of the: "Observational Study Evaluating Efficacy and Costs of Secondary Prophylaxis vs On-demand Therapy With Kogenate Bayer in Patients With Severe Haemophilia A."

NCT02581969 · clinicaltrials.gov ↗

COMPLETED

Status

43

Enrollment

INDUSTRY

Sponsor class

Conditions

Hemophilia A

Interventions

DRUG: Recombinant Factor VIII (Kogenate FS, BAY14-2222)
DRUG: Recombinant Factor VIII (Kogenate FS, BAY14-2222)

Sponsor

Bayer